Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 2,817 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sample Collection Blood Clear all

Conditions: Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Gray-Zone Lymphoma
Interventions: Polatuzumab Vedotin, Rituximab, Prednisone, Etoposide, Doxorubicin, Cyclophosphamide, Glofitamab, Multigated Acquisition Scan, Echocardiography Test, FDG-Positron Emission Tomography, Computed Tomography, Bone Marrow Biopsy, Biospecimen Collection, Bone Marrow Aspiration; Drug · Biological · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Thromboelastography, Coagulation; Fetus or Newborn, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes, Gestational
Interventions: Laboratory clotting studies; Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 0 Hours to 2 Hours
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Gynecologycal Cancer
Interventions: muscle sample, blood draw; Diagnostic Test · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer, Triple Negative Breast Cancer (TNBC), Renal Cell Carcinoma (Kidney Cancer), Head and Neck Squamous Cell Carcinoma HNSCC
Interventions: Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing; Other · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 16
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more

Conditions: Chromosome 13 Aneuploidy, Chromosome 18 Aneuploidy, Chromosome 21 Aneuploidy, Sex Chromosome Aberrations, Other Microdeletions
Interventions: Blood draw, Cheek swab/Saliva Sampling; Procedure
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,781 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Prenatal Diagnosis, Genetics
Interventions: Non Invasive Prenatal Test via blood sample; Other
Lead sponsor: Identifai Genetics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Glioblastoma
Interventions: 89Zr-J591, PET/CT Scan, MRI, Blood draw; Drug · Device · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 26 Years to 79 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Neoplasms, Carcinoma Non-small-cell Lung, Adenocarcinoma
Interventions: Multifocal Lung Adenocarcinoma; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
Interventions: Arm 1; Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Down Syndrome, Alzheimer's Dementia
Interventions: biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy; Procedure · Other
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 21 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Cystic Fibrosis
Interventions: Blood or Saliva Sample Collection; Genetic
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Delirium
Interventions: High Density-Electroencephalogram, Magnetic Resonance Imaging, Blood specimen collection, Pupillometry; Procedure · Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 60 Years and older
Enrollment: 468 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Blood Draws and Tissue Sample(s); Other
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Interventions: Arginine, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Spectroscopy, Whole-Brain Radiotherapy; Drug · Procedure · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Malignant Brain Neoplasm, Malignant Solid Neoplasm, Multiple Sclerosis, Neuroendocrine Tumor, Prostate Carcinoma
Interventions: Biospecimen Collection, Exercise Intervention, Magnetic Resonance Imaging, Questionnaire Administration, Respiratory Therapy; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 147 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Epilepsy
Interventions: blood draw; Other
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: Sun City, Arizona • Boise, Idaho • Lexington, Kentucky + 4 more

Conditions: Brain and Central Nervous System Tumors
Interventions: bevacizumab, sorafenib tosylate; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 204
States / cities: Scottsdale, Arizona • Fresno, California • Fort Collins, Colorado + 129 more

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: Aqtual, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 42
States / cities: Phoenix, Arizona • Apple Valley, California • Covina, California + 38 more

Conditions: Meningococcal Infection (Healthy Volunteers)
Interventions: Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Blood sample; Biological · Other
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 59 Years and older
Enrollment: 471 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 33
States / cities: Chandler, Arizona • San Diego, California • Waterbury, Connecticut + 27 more

Conditions: Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions: Celecoxib, Durvalumab, Tremelimumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Biopsy Procedure; Drug · Biological · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Postural Orthostatic Tachycardia Syndrome
Interventions: History, Physical, blood draw, Questionnaires; Other · Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 13 Years to 80 Years
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation
Interventions: Cisplatin, Carboplatin, Paclitaxel, Vidaza, Tumor Specimen for Methylation Analysis, Blood Sample for Methylation Analysis, Vinorelbine, Docetaxel, Pemetrexed; Drug · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Resectable Hepatocellular Carcinoma
Interventions: Biospecimen Collection, Electronic Health Record Review; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteers, Syphilis Serologic Assay Development, Blood Specimen Collection, Diagnostic Assay Development, Serum Specimen Collection
Interventions: ALPCO Syphilis-T, ALPCO Syphilis-NT CLIA Kits; Device
Lead sponsor: American Laboratory Products Company; Industry
Eligibility: 22 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Salem, New Hampshire

Search by objective public record fields.

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Thromboelastographic Profile in Healthy Newborns and Infants of Diabetic Mothers Using TEG6s

Role of Mitochondrial Bioenergetics in Resilience for Gynecologic Cancer

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Non-invasive Prenatal Diagnostic Validation Study

Identifai Genetics Analytic Validity Study - Compound Heterozygosity and Samples Collection

89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

Treatment of Multifocal Lung Adenocarcinoma

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)

Genetics of Insulin and Incretins in Cystic Fibrosis

Interventions for Postoperative Delirium: Biomarker-3

Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck

Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases

Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases

Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)

Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Assessment of Antibodies and Inflammatory Markers in Postural Tachycardia Syndrome

Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy

Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer

Blood Donation Study for ALPCO Syphilis-T and Syphilis-NT Assay Development